Fibrates and statins are associated with a 42-fold and 8-fold increased risk of myopathy, respectively, compared to normal controls, but the incidence remains low, at 6 per 100,000 and 1 per 100,000, respectively.
The results of 3 recent investigations suggest that immunotherapy still has the potential to become a treatment for AD but that the road to its successful development is likely to be a long one.
Considerable concern exists among clinicians regarding the risk-benefit ratio of long-term anticoagulation compared to antiplatelet treatment. In order to compare the risk of vascular events and bleeding complications in patients with AF, van Walraven and associates analyzed data from 6 randomized clinical trials.
Aripiprazole (Abilify), a new drug for schizophrenia, received FDA approval November 15; on November 14, Neurocrine Biosciences Inc. announced positive results from its first phase III clinical trial with indiplon-IR achieving primary and secondary end points of sleep initiation.
FDA Approves Claritin For OTC Use For Seasonal Rhinitis; Simpler Atrial Fibrillation Management; Oral Anticoagulation Vs Aspirin in AF; Immunization Does Not Cause Autism; Statins May Lower CRP Levels; Simvastatin Reduced CRP Plasma Levels; FDA Actions
Effects of Losartan on Cardiovascular Morbidity and Mortality in
Patients with Isolated Systolic Hypertension and LVH; Increase in
Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1
Diabetes; HRT, Lipid, and Glucose Metabolism in Diabetic and
Nondiabetic Postmenopausal Women; Effects of Long-Term Treatment With
ACE Inhibitors in the Presence or Absence of Aspirin; Long-Term Risks
Associated with Atrial Fibrillation: 20-Year Follow-up of the
Renfrew/Paisley Study; Olfactory Impairment in Older Adults